

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 882 736 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

09.12.1998 Bulletin 1998/50

(51) Int. Cl.⁶: C07K 7/23

(21) Application number: 97401212.2

(22) Date of filing: 02.06.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant:
LABORATOIRE THERAMEX S.A.
98000 Monaco (MC)

(72) Inventors:
• Delansorne, Rémi
06000 Nice (FR)

• Paris, Jacques
06100 Nice (FR)

(74) Representative:
Nevant, Marc et al
Cabinet Beau de Loménie,
158, rue de l'Université
75340 Paris Cedex 07 (FR)

(54) LH-RH peptide analogues, their uses and pharmaceutical compositions containing them

(57) The invention relates to LH-RH peptide analogues with excellent affinity for LH-RH receptors, of the formula :

A1-A2-A3-A4-A5-A6-Npg-A7-Pro-Z (I)

The invention also relates to the uses of said peptide analogues and to the pharmaceutical compositions containing them.

EP 0 882 736 A1

Description

This invention relates to LH-RH peptide analogues, to their use and to pharmaceutical compositions in which they are present.

5 LH-RH, or luteinizing hormone-releasing hormone, is a neurohumoral hormone produced in the hypothalamus, which stimulates the secretion of the gonadotrophins, LH (luteinizing hormone) and FSH (follicle-stimulating hormone), which in turn regulate the endocrine and exocrine functions of the ovary in the female, and of the testis in the male. It has the following structural formula :

10 1 2 3 4 5 6 7 8 9 10



15 Historically (Karten and Rivier, Endocr. Rev., 1986, 7(1), 44-66), synthetic improvement of LH-RH activity has been achieved first, by replacement of the C-terminal glycinate by a ethylamide directly bound to Pro⁹, and then, by introduction of D-Ala in position 6. Both independent breakthroughs yielded analogs each about 5 times more active than LH-RH. All therapeutically useful agonists result from further major improvement in position 6 with the introduction of hydrophobic aliphatic or aromatic D-amino acids instead of D-Ala, with or without the combined Pro⁹-N-ethylamide modification. On this C-terminal end, only slight improvements have been obtained with fluorinated amides or with aza-glycinate. Replacement of Trp in position 3 by 1Nal has been reported (Karten and Rivier, 1986, cf above) to give an agonist twice as potent as LH-RH, without further synthetic or therapeutic developments.

20 The only other individual amino acid modification noticed to increase the biological activity of some agonists was found in position 7. Thus, N-methylation of Leu⁷ in LH-RH itself did not increase its potency, but enhanced the activity of some already potent synthetic agonists with certain D-amino acids in position 6 such as D-Trp (Karten and Rivier, 1986, cf above); furthermore, charged and bulkier L-amino acids than leucine (Ser(OBu¹), Asp(O-Bu¹), Glu(O-Bu¹), BocLys) somewhat improved the activity of [des-Gly¹⁰; Pro⁹-N-ethylamide]-LH-RH but reduced the potency of 6-modified agonists (Karten and Rivier, 1986, cf above).

25 As far as antagonists are concerned, numerous modifications in all positions but Pro⁹, and a wide variety of combinations among them, have been tried with unequal success to achieve inhibition of endogenous LH-RH activity (Dutta, Drugs of the Future, 1988, 13(8), 761-787; Karten and Rivier, Endoc. Rev., 1986, 7(1), 44-66). For example, N-antide, a standard potent LH-RH antagonist, results from amino acid changes in positions 1, 2, 3, 5, 6, 8 and 10. N-methylation of Leu⁷ brought about a decrease in potency, and the only changes in this position reported to increase it (2-fold maximum) were the replacement of Leu⁷ by Trp⁷ or Phe⁷.

30 35 It has now been found that the replacement of Leu⁷ by neopentylglycine (Npg) increases the activity of LH-RH itself and makes it possible to obtain analogs with a high affinity for the LH-RH receptor. More specifically, the [Npg⁷]-LH-RH analogues of this invention are potent LH-RH agonists / antagonists *in vivo*.

35 Thus, according to one aspect of the present invention, LH-RH peptide analogues with high affinity for the LH-RH receptors are provided, in which Npg⁷ is substituted for Leu⁷. Preferably these peptides are of the formula (SEQ ID N° 40 : 1):



in which:

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or a aromatic D-amino acid which may be acylated, such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A2 is a direct bond ; His ; or a aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A3 is a aromatic L- or D-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu¹), Ser(OBzI) or Thr;
- A5 is a aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACh, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, Cit, HCit, APhe and ACh may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nico-

tinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group; pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group; A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl azaGly or azaAla ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-group ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenlyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthalogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group; glycyl, Fmoc or Boc group; Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms; A7 is a basic L-or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg or HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, ad where Orn may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe or ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group; Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by an hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl, or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl; as well as their pharmaceutically acceptable salts.

In the present description the term "(C₁-C₄)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl groups.

The term "(C₁-C₆)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl and hexyl groups.

The term "(C₁-C₈)alkyl" denotes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl, hexyl, heptyl and octyl groups ;

The term "(C₁-C₄)alkoxy" denotes a group -OR where R is a (C₁-C₄)alkyl.

The term "(C₂-C₇)acyl" denotes a group -COR where R is a (C₁-C₆)alkyl.

The term "(C₃-C₆)cycloalkyl" denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.

The term "sugar moiety" denotes D- or L-pentoses or hexoses and their amino-derivatives.

The term "LH-RH analogues" denotes peptides in which at least one amino acid has been modified in the sequence of LH-RH.

In the present description and in the claims, the following abbreviations are used :

Abu : 2-aminobutyric acid
 Ac : acetyl
 45 ACh : aminocyclohexylalanine
 Aib : 2-aminoisobutyric acid
 3Aib : 3-aminoisobutyric acid
 Ala : alanine
 AlaNH₂ : alaninamide
 50 APhe : p-aminophenylalanine
 Arg : arginine
 Asp : aspartic acid
 azaAla : aza-alanine
 azaGly : aza-glycine
 55 azaGlyNH₂ : azaglycinamide
 Bal : benzothienylalanine
 Boc : *tert*-butoxycarbonyl
 Cba : cyclobutylalanine

	Cha : cyclohexylalanine
	Cit : citrulline
	CPa : cyclopropylalanine
	Cpa : cylopentylalanine
5	Fmoc : fluorenylmethoxycarbonyl
	For : formyl
	Glu : glutamic acid
	Gly : glycine
	GlyNH ₂ : glycynamide
10	HArg : homoarginine
	HCit : homocitrulline
	His : histidine
	HLys : homolysine
	Hol : homoleucine
15	Ile : isoleucine
	IprLys : N ^ε -isopropyllysine
	Leu : leucine
	Lys : lysine
	MeSer : N-methylserine
20	Met : methionine
	Nal : 3-(2-naphthyl)alanine
	1Nal : 3-(1-naphthyl)alanine
	NET : N-ethylamide
	NicLys : N ^ε -nicotinoyllysine
25	Nle : norleucine
	Npg : neopentylglycine
	Nva : norvaline
	OBu ^t : <i>tert</i> -butoxy
	OBzl : benzyl ester
30	Orn : ornithine
	Pal : 3-(3-pyridyl)alanine
	pCIPhe : 3-(4-chlorophenyl)alanine
	Pen : penicillamine
	pGlu : pyroglutamic acid
35	Phe : phenylalanine
	Pro : proline
	Qal : 3-(3-quinolyl)alanine
	Sar : sarcosine
	Ser : serine
40	(S-Me)Pen : S-methyl-penicillamine
	(S-Et)Pen : S-ethyl-penicillamine
	Thr : threonine
	Tle : <i>tert</i> -leucine
	Trp : tryptophan
45	Tyr : tyrosine
	Val : valine

A preferred group of peptides according to the invention, having LH-RH agonist activity, comprises the peptides of the formula (SEQ ID N° : 2):

50 A1-A2-A3-A4-A5-A6-Npg-A7-Pro-Z (IIa)
in which:

- A1 is pGlu, Sar or AcSar;
- A2 is His;
- 55 - A3 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;
- A5 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp

- may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(R₁) where R₁ is a sugar moiety ; an aza-amino acid such as azaGly or azaAla ; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenlyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid such as D-Arg, D-HArg, D-Orn, D-Lys, D-HLys, D-Cit, D-HCit, D-APhe or D-ACha, where D-Arg and D-HArg may be N-substituted by a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where D-Orn, D-Lys, D-HLys, D-APhe and D-ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a Fmoc or Boc group;
 - Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;
 - A7 is a basic L-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha;
 - Z is GlyNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by a hydroxy or one or several fluorine atoms, a (C₃-C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl; as well as their pharmaceutically acceptable salts.

Another preferred group of peptides according to the invention, having LH-RH antagonistic activity, comprises the peptides of the formula (SEQ ID N° : 3):

A1-A2-A3-A4-A5-A6-Npg-A7-Pro-Z (IIb)

in which:

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof such as AcPro, ForPro, OH-Pro, Ac-OH-Pro, dehydro-Pro or Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A2 is a direct bond or an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A3 is an aromatic L- or D-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;
- A5 is an aromatic L-amino acid such as Phe, Tyr, Trp, Nal, 1Nal, diphenyl-Ala, Bal, Pal or Qal, where Phe and Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;
- A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(R₁) where R₁ is a sugar moiety ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain such as D-Ala, D-Abu, D-Aib, D-3Aib, D-Val, D-Nva, D-Leu, D-Ile, D-Tle, D-Nle, D-Hol, D-Npg, D-CPa, D-Cpa, D-Cba or D-Cha ; an aromatic D-amino acid such as D-Phe, D-Tyr, D-Trp, D-Nal, D-1Nal, D-diphenyl-Ala, D-anthryl-Ala, D-phenanthryl-Ala, D-benzhydryl-Ala, D-fluorenlyl-Ala, D-Bal, D-Pal or D-Qal, where D-Phe and D-Trp may be substituted by one or more halogens, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, nitro or trifluoromethyl groups ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn, Lys, HLys, APhe and ACha may be N-substituted by one or two (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group;
- Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;
- A7 is a basic L- or D-amino acid such as Arg, HArg, Orn, Lys, HLys, Cit, HCit, APhe or ACha, where Arg and HArg may be N-substituted by a (C₁-C₆)alkyl or (C₃-C₆)cycloalkyl group on one or both nitrogen atoms, and where Orn,

Lys, HLys, APhe and ACha may be N-substituted by one or two (C_1 - C_6)alkyl or (C_3 - C_6)cycloalkyl groups, or by a nicotinoyl, isonicotinoyl, 6-methyl-nicotinoyl, glycyl-nicotinoyl, nicotinyl-azaglycyl, furyl, glycyl-furyl, furyl-azaglycyl, pyrazinyl, pyrazinyl-carbonyl, picolinoyl, 6-methyl-picolinoyl, shikimyl, shikimyl-glycyl, Fmoc or Boc group; Z is GlyNH₂ or D-AlaNH₂; as well as their pharmaceutically acceptable salts.

- 5 Among the peptides of formula (IIa), those of the formula (SEQ ID N° : 4):
 pGlu-His-Trp-Ser-Tyr-A6-Npg-Arg-Pro-Z (IIIa)

in which :

- 10 - A6 is Gly ; an aliphatic D-amino acid with a (C_1 - C_8)alkyl side chain ; or an aromatic D-amino acid ;
 - Npg is optionally N-alpha-methylated ;
 - Z is GlyNH₂ or a group - NH₂C₂H₅ ;
 and their pharmaceutically acceptable salts,
 are especially preferred.

- 15 Among the peptides of formula (IIb), those of the formula (SEQ ID N° : 5):
 Ac-D-Nal-D-pCIPhe-D-Pal-Ser-A5-A6-Npg-A7-Pro-D-AlaNH₂ (IIIb)
 in which :

- 20 - A5 and A7 are as defined above for (IIb) ;
 - A6 is Gly or a basic L- or D-amino acid ;
 - Npg is optionally N-alpha-methylated
 and their pharmaceutically acceptable salts,
 are especially preferred.

25 Examples of the salts with pharmaceutically acceptable acids are those with mineral acids, such as for example the hydrochloride, hydrobromide, sulfate, phosphate, borate, hydrogensulfate, dihydrogenphosphate or nitrate, and those with organic acids, such as for example the acetate, oxalate, tartrate, succinate, maleate, fumarate, gluconate, citrate, pamoate, malate, ascorbate, benzoate, p-toluenesulfonate or naphthalenesulfonate.

30 Examples of the salts with pharmaceutically acceptable bases are those with alkali or alkaline earth metals such as sodium, potassium, calcium or magnesium, and those with organic bases such as amines, trometamol, N-methyl-glutamine, and the like.

The peptides according to the present invention can be prepared by the well-known techniques of peptide chemistry such as for example peptide synthesis in solution or solid phase peptide synthesis. In general, these techniques involve the stepwise addition of one or more amino acids -which may be suitably protected- to a forming peptide chain.

35 Preferably, the peptides according to the invention are synthesized using stepwise solid phase synthesis (1,2) with N- α -Fmoc protection. For example, the peptides are assembled on a 4-methylbenzylhydrylamine resin (Peninsula Laboratories, UK) or on an aminomethyl resin (Peninsula Laboratories, UK). The C-terminal proline is introduced as 4-(Boc-
 Prolyloxymethyl)phenyl acetic acid. Subsequent removal of the Boc protecting group is achieved with trifluoroacetic acid followed by dichloromethane and dimethylformamide (DMF) washing as well as diisopropylethylamine neutralization. It is also possible to use a "Rink" resin (4-(2',4'-dimethoxyphenyl)-Fmoc-aminomethylphenoxy resin) using Fmoc strategy of synthesis (2).

40 The synthesis comprises assembling, cleavage and purification steps, as described below :

45 1. Assembling

For all the peptides the following deprotection/coupling procedure is used :

- 50 1 - DMF washing (3 times - 1 min.)
 2 - Piperidine 25 % in DMF (1 min.)
 3 - Piperidine 25 % in DMF (twice - 15 min.)
 4 - DMF washing (7 times - 1 min.)

For each step 15 ml of solvent per gram of peptide resin are used.

55 Coupling of all amino acid (three fold excess) is performed in DMF in the presence of BOP, HObt and DIEA (3). Each coupling step is controlled for completion by the ninhydrine test (4) and double coupling is performed if necessary. If, after the second coupling the test still remains positive, the resin is acetylated (acetic acid anhydride, 10 fold excess and DIEA).

Generally, a trifluoroacetic acid (TFA) treatment is performed prior to the deprotection/cleavage step.

II. Cleavage

5 The peptides are cleaved from the resin and fully deprotected by a treatment with either liquid hydrogen fluoride (HF) or TFA. 10 ml of HF or TFA per gram of peptide resin are used classically at 0° C for 45 min. or 2.5 hours, respectively, in the presence of p-cresol and ethanedithiol (for tryptophan-containing peptides) as scavengers.

After evaporation of the HF, the crude reaction mixture is washed with diethyl ether, dissolved in TFA, precipitated with diethyl ether and dried under reduced pressure.

10 If need be, prior to HF deprotection the peptide is cleaved from the resin and subsequently amidated by a treatment with ethylamine (5 ml ethylamine per gram of peptide resin, - 78°C, 20 hours).

When a benzyl group is present in the final product, TFA is used (10 ml per gram of peptide resin, 0° C, 2.5 hours) for the final cleavage/deprotection.

The composition of the TFA cleavage mixture in v % is the following :

15	TFA	: 83.3%
	Ethanedithiol	: 2.1%
	Thioanisol	: 4.2%
	Water	: 4.2%
20	Phenol	: 6.2 %

After filtration of the resin, the peptide is precipitated from the reaction mixture by addition of a large amount of diethylether. After several washings with diethylether the crude peptide is dried under reduced pressure.

III. Purification

All the peptides are purified by reverse phase liquid chromatography.

The general procedure of purification is identical for each peptide ; however the gradient of organic solvent is adjusted depending on the initial retention time of the peptide.

General conditions of purification :

Equipment	: KRONWALD SPERATIONSTECHNIK, Medium Pressure liquid chromatography system (Germany) equipped with Glass column.
35 Stationnary phase	: silica Bondapack C18 (Waters) 15-25 µm, 100 Å
Size of column	: 40 x 340 mm
Elution conditions:	
Mobile phase:	Eluant A : 0.1 % TFA in water Eluant B : CH ₃ CN/A 60/40 (volume)
40 Temperature	: Room
Flow rate	: 40 ml
Detection	: UV 210 nm
Fractioning	: 5 ml per fraction

45 All fractions containing the target compound are individually analyzed by analytical HPLC. The fractions with a purity higher than 95 % are pooled and freeze-dried. In case the requested purity is not reached after the first purification step, a second purification step and, if need be, a third purification step are performed. The conditions of purification for the second and third steps are similar as those described above except that the slope of the gradient is modified in order to increase the resolution.

50 After lyophilisation, all purified peptides are present as their trifluoroacetate salt. The final powder corresponding to each peptide is controlled by analytical HPLC. The structure of each compound is also assessed by mass spectral analysis and the net peptide content is determinated by UV absorption.

The peptides according to the present invention have a potent affinity for the LH-RH receptors.

This affinity has been determined according to the following method:

55 Pituitaries from female Sprague Dawley rats were removed and homogenized with a Potter homogenizer in a 25 mM HEPES buffer (pH 7.4) containing 0.32 M sucrose, 100 µg/l PMSF (phenylmethylsulfonylfluoride), 5.6 U/l aprotinin and 10 000 U/l bacitracin. The homogenates were centrifuged at 700 g for 10 minutes and the supernatants were further centrifuged at 12,500 g for 30 minutes. The pellets were homogenized and centrifuged as described above, but in

the same buffer without sucrose.

All homogenization, centrifugation and subsequent incubation steps were carried out at 4° C.

Aliquots of membrane fractions were incubated for 2 hours in duplicate with increasing concentrations of test compounds in the presence of 20 to 70 pM of [¹²⁵I]-buserelin (between 1000 and 2000 Ci/mmol depending on ligand batches). The assay was terminated by filtration under suction (Brandel 96-well harvester) through Whatman GF/B glass fiber filters. After repeated washes, filters were placed in counting vials with scintillation cocktail to measure the radioactivity of ¹²⁵I. For each experiment, curve-fitting of residual specific binding against concentrations of test compound gave the 50% inhibitory concentration (IC₅₀). Each compound was tested in at least 4 experiments.

This LH-RH receptor assay was characterized by 4 saturation experiments using increasing concentration of [¹²⁵I]-buserelin in the absence or presence of 1 μM unlabelled buserelin for non specific binding determination. Specific binding data were analysed according to Scatchard's method. At equilibrium (2 hours of incubation), the dissociation constant (Kd) and the number of binding sites for [¹²⁵I]-buserelin were respectively equal to 88 ± 6 pM and 15.6 ± 2.9 pM.

For each test compound, the inhibitory constant (Ki) was calculated from its IC₅₀ according to the Cheng and Prussoff's equation : Ki = IC₅₀ / (1 + [radioligand]/Kd). Ki were then transformed into pKi (= - log Ki) for final expression of affinity scales.

The natural ligand, LH-RH itself, displays a strong affinity with experimental IC₅₀ in the 10 nM range, i.e., a pKi equal to about 8.

So-called superagonists like buserelin, leuprorelin, tryptorelin, histrelin or deslorelin and antagonists like antide show an even stronger binding to LH-RH receptors with IC₅₀ in the subnanomolar range, i.e. pKi > 9.

The affinity of test peptides of the invention for the LH-RH receptors is given in Table 1 below :

Table 1

Affinity for LH-RH receptors				
	Compound	pKi (n)	Compound	pKi (n)
25	Example 1	8.83 (3)	Example 14	9.50 (3)
30	Example 2	9.61 (3)	Example 15	9.23 (3)
35	Example 3	9.57 (3)	Example 16	10.17 (3)
40	Example 4	10.01 (3)	Example 17	9.72 (3)
45	Example 5	8.86 (3)	Example 18	10.07 (3)
	Example 6	9.33 (3)	Example 19	10.11 (3)
	Example 7	8.20 (3)	LH-RH	8.04 (4)
	Example 8	8.73 (3)	Goserelin	8.58 (4)
	Example 9	8.63 (3)	Antide	9.16 (12)
	Example 10	9.64 (3)	Leuprorelin	9.33 (4)
	Example 11	9.34 (3)	Buserelin	9.35 (108)
	Example 12	9.79 (4)	Tryptorelin	9.85 (4)
	Example 13	8.97 (3)	Deslorelin	9.90 (4)
			Histrelin	9.98 (4)

(n) : number of determinations

50 The peptides according to the general formula (IIa) exert an agonist activity upon the LH-RH receptors *in vivo*, resulting in the stimulation of LH secretion by the pituitary, which, in males, stimulates the secretion of testosterone by the testis.

Adult male Sprague-Dawley rats received a subcutaneous injection of various doses of LH-RH, tryptorelin or leuprorelin, or their respective counterpart with Npg⁷ replacing Leu⁷ : example 1 ([Npg⁷]-LH-RH), example 6 ([Npg⁷]-leuprorelin) or example 11 ([Npg⁷]-tryptorelin), dissolved in phosphate-buffered saline (PBS). Two hours later, blood samples were drawn for total plasma testosterone determination by direct radioimmunoassay (Immunotech). Example I was a little more than twice as active as LH-RH itself, and the other compounds behaved like so-called (superagonists) by inducing a stronger stimulation of testosterone secretion at much lower doses (logarithmic x axis)

than LH-RH (Figure 1; 8 animals per point). At 20 ng/kg, the secretion of testosterone was equally maximally stimulated by the four superagonists (exponential y axis scale), but at 10 ng/kg, examples 6 and 11 were a little more than twice as active as leuprorelin and tryptorelin, respectively.

At the same dose of 10 ng/kg, examples 4, 12, 3 and 10 were respectively 1.2, 1.7, 2.6 and 5 times more active than their [Leu⁷]-parent-compound. Thus, when available from Bachem or Sigma, the known LH-RH agonists were all less potent than their corresponding example according to the present invention relating to the advantage of Npg⁷ over Leu⁷. The level of stimulation obtained by examples 5 and 13, although not in direct comparison with their Leu⁷ counterpart, was also very high, similar to that of leuprorelin and tryptorelin, and example 9 displayed an even higher potency, similar to that of examples 6 and 11. The above results are shown in Table 2 below or in Figure 1.

10

Table 2

Stimulation of testosterone secretion				
	Compound	Dose (ng/kg)	Total plasma testosterone (nmol/l)	n
15	Vehicle (PBS)	--	0.8 ± 0.2	20
20	[D-Ala ⁶]-LH-RH	10	6.4 ± 1.9 *	8
25	Example 3	10	16.7 ± 1.9 ***	8
30	[D-Ala ⁶ , Pro ⁹ NEt]-LH-RH	10	11.1 ± 3.3 **	8
35	Example 4	10	12.9 ± 1.3 ***	8
40	[D-Phe ⁶ , Pro ⁹ NEt]-LH-RH	10	2.8 ± 0.5 *	8
45	Example 10	10	14.1 ± 3.0 ***	8
50	Deslorelin	10	11.8 ± 3.5 **	6
55	Example 12	10	20.5 ± 5.2 ***	6
60	Example 5	10	21.2 ± 6.6 ***	6
65	Example 9	10	30.9 ± 3.6 ***	8
70	Example 13	10	22.9 ± 4.2 ***	6

n : number of animals

* p < 0.05 ;

** p < 0.01 ;

*** p < 0.001 compared to vehicle alone

The peptides according to the general formula (IIb) exert an antagonistic activity upon the LH-RH receptors *in vivo*, resulting in the inhibition of ovulation in the female.

Adult female Wistar rats are first monitored for normal estrous cyclicity by daily vaginal smears. After at least 2 regular 4-day cycles, they received by subcutaneous injection either the vehicle alone (0.5 ml of a mixture of propylene glycol and water : 20/80 vol/vol), or the LH-RH antagonist according to the formula (IIb) dissolved in this vehicle, around 2:00 PM on the day of proestrus. All but one vehicle-treated animals ovulated spontaneously as demonstrated by the recovery of numerous ovocytes in the oviducts the following morning.

If effective, LH-RH antagonists totally block ovulation. Antide, a commercially available standard LH-RH antagonist (from Bachem), was sub-maximally active at the dose of 1 µg/rat but lost most of its potency at the dose of 0.5 mg/rat. Replacement of Leu⁷ by Npg⁷ in antide resulted in an increased activity at the even lower dose of 0.25 µg/rat (Example 15). Examples 16, 18 and 19 appeared slightly more active than antide and example 17 was the most potent compound, showing that Npg⁷ is compatible with various combinations of basic amino acids in positions 6 and 8 that are characteristic of most other standard LH-RH antagonists such as cetrorelix or antarelix. With still sub-maximal efficacy to inhibit ovulation at the dose of 0.25 µg/rat, example 17, and to a lesser extent example 15, are especially promising. The above results are shown in Table 3.

55

Table 3

Inhibition of ovulation		
Treatment	Dose ($\mu\text{g/rat}$)	Number of ovulating females /total number of treated females
Vehicle	--	27/28
Antide	5	0/5
	1	1/8
	0.5	4/5
[Npg ⁷]-Antide (Example 15)	1	1/5
	0.25	2/5
Example 16	1	0/5
	0.25	4/5
Example 17	1	0/5
	0.25	1/5
Example 18	1	1/5
	0.25	4/5
Example 19	1	0/5
	0.25	3/5

In conclusion of both agonist and antagonistic studies *in vivo*, it has been shown that replacement of Leu⁷ by Npg⁷

30 in LH-RH analogues gives compounds with at least equivalent therapeutic potential or, more frequently, increases the potency of existing analogues. Moreover, other peptides according to the invention that are not direct counterparts of known therapeutic LH-RH analogues, displayed an even greater potency. The use of neopentylglycine in place of leucine in position 7, or in any homologous position, is therefore claimed as a general structural feature useful in the design of any new LH-RH analogue.

35 No sign of toxicity is observed with the peptides of the invention at pharmaceutically active doses.

Thus, the peptides of the invention and their pharmaceutically acceptable salts may be used in the treatment or prevention of various complaints or diseases wherein a LH-RH agonist or antagonist activity is required.

The main target of LH-RH analogues is the pituitary gland, but direct actions have been reported on the gonads themselves (testis and ovary), on the thymus and some lymphoid cell lines, on mast cells and on breast, prostate or pancreatic tumors.

40 LH-RH agonists according to formula (IIa) exert on any LH-RH sensitive target, either a stimulatory activity by short-term acute or pulsatile administrations, or an inhibitory effect by repeated or continuous administrations that induce the desensitization and the down-regulation of LH-RH receptors. In the case of the hypothalamo-pituitary-gonadal axis, prolonged administration results in a so-called "chemical" castration.

45 LH-RH antagonists according to formula (IIb) exert primarily an inhibitory effect on any LH-RH-sensitive target, but are also useful in obtaining or planning a rebound stimulatory release of LH and FSH when treatment is discontinued.

Due to this ambivalent potential of both LH-RH agonists and antagonists, all analogues according to formula (I) can find an appropriate therapeutic use in humans as well as in animals, depending on doses, treatment regimens and routes of administration, in reproductive endocrinology and in the treatment or prevention of sex hormone-dependent benign or malignant tumors, alone or in combination with other hormonal or antitumoral agents. LH-RH sensitive sex hormone-independent benign or malignant tumors can also regress upon treatment with LH-RH analogues according to formula (I), alone or in combination with antitumoral agents. Immune mechanisms can also be modified by LH-RH analogues according to formula (I), alone or in combination with immuno-modulating or -suppressive agents such as glucocorticoids, cyclosporin, rapamycin, tacrolimus, their derivatives, and the like. The LH-RH analogues according to the invention are therefore very valuable in the treatment and prevention of autoimmune diseases, graft rejection or atopic diseases, and in the treatment of benign or malignant lymphoproliferative disorders.

55 LH-RH analogues according to formula (I) are especially useful, alone or in combination with sex steroids or gonadotrophins, in the inhibition, planning and triggering of ovulation in *in vitro* fertilization programs, and in the treatment of

male and female infertility or hypogonadic states. Conversely, they can also be used in male or female contraception or treatment of hypergonadic states, alone or in combination with sex steroids or gonadotrophins. This applies to men and women, but also to wild or domestic animals in uses such as improvement or control of reproductive performance, or as a tool to optimize breeding strategies.

5 LH-RH analogues according to formula (I) are also especially useful in men to treat advanced prostate cancer, but can also be used as a first line therapy in this indication and in benign prostatic hypertrophy, alone or in combination with inhibitors of androgen action, i.e. antiandrogens such as cyproterone acetate, osaterone acetate, chlormadinone acetate, flutamide, nilutamide or bicalutamide and the like, or 5 α -reductase inhibitors such as finasteride, epristeride or turosteride and the like, or C₁₇₋₂₀ lyase inhibitors such as abiraterone and the like.

10 LH-RH analogues according to formula (I) are also especially useful in the treatment or prevention of breast cancer in women and in men, especially estrogen receptor positive tumors, alone or in combination with antiestrogens such as tamoxifen, raloxifen or droloxifen and the like, or with aromatase inhibitors such as atamestane, formestane, letrozole, anastrozole and the like, or with C₁₇₋₂₀ lyase inhibitors such as abiraterone and the like, but also of certain estrogen receptor negative tumors that respond to the direct effects of LH-RH analogues or indirectly to their gonadal suppressive activity.

15 Other gynecological conditions, such as endometrial hyperplasia, leiomyoma, adenomyoma, endometriosis, polycystic ovary syndrome, hirsutism and benign breast disease (pain, cysts or fibrosis), can also be prevented by or benefit from treatment with the LH-RH analogues according to formula (I), alone or in combination with antiestrogens (cited above), progestins such as cyproterone acetate, osaterone acetate, chlormadinone acetate, nomegestrol acetate, 20 promegestone, demegestone, trimegestone and the like, or their contraceptive or post-menopausal replacement combination formulations with estrogens such as estradiol or ethynodiol. The peptides of the invention can also interfere with gestation by inducing abortion or by triggering labor, alone or in combination with estrogens (cited above), antiprogestins such as mifepristone or prostaglandin analogs such as sulprostone.

25 Similar indications can be encountered in veterinary medicine for male or female domestic or wild animals that may require the use of LH-RH analogues according to formula (I).

Another aspect of the present invention is therefore pharmaceutical compositions containing an effective amount of at least one peptide of formula (I) or a pharmaceutically acceptable salt thereof, alone or mixed with suitable pharmaceutical excipients.

30 A further aspect of the invention relates to a method of treating and/or preventing the above diseases which comprises administering to patients or animals in need thereof a therapeutically effective amount of a peptide of formula (I) or a pharmaceutically acceptable salt thereof.

35 A further aspect of the invention relates to the use of the peptides of formula (IIa), or of their pharmaceutically acceptable salts, for the preparation of a medicament having LH-RH agonist activity. Also within the scope of the invention is the use of the peptides of formula (IIb), or of their pharmaceutically acceptable salts, for the preparation of a medicament having LH-RH antagonist activity.

40 The peptides of the invention are preferentially administered by parenteral administration, although oral formulations are also effective provided that the dosage is appropriately increased.

Preferred delivery systems for LH-RH agonists of formula (IIa) in long term pituitary-gonadal suppressive indications are slow-release implantable devices, or injectable biodegradable polymeric micro- or nano-particles or -capsules, 45 or micro- or nano-emulsions, with unit doses of the peptides or of their appropriate salts ranging from 1 mg to 100 mg per human patient for a duration of action ranging from 1 month to 1 year. Long term administration of LH-RH antagonists of formula (IIb) will generally require higher dosages in the same slow-release formulations, ranging from 10 mg to 1 g for 1 week to 1 year of activity. Animal doses will be adapted on a body weight basis depending on the wild or domestic species to be treated either by LH-RH agonists or antagonists according to formula (I).

45 All other means of parenteral administration are suited for immediate, delayed or planned delivery of the peptides of the invention : subcutaneous, intramuscular, intravenous, intragonadal or intratumoral needle bolus injections, or prolonged continuous, pulsatile or planned perfusions or microinfusions using the appropriate pump technology; gas-propelled subcutaneous microinjection ; vaginal creams, gels or pessaries ; rectal enemas or suppositories ; transdermal creams, gels, lotions, solutions, patches or iontophoretic devices ; nasal spray or dry powder inhalation device ; ophthalmic solutions, gels, creams or contact lenses ; pulmonary inhalation of micro- or nano-particles or droplets generated manually or with an appropriate pulverization or nebulization device.

50 The unit dose of these parenteral administrations will range in humans from 0.001 mg to 10 mg/day for LH-RH agonists of formula (IIa) and from 0.01 to 100 mg/day for LH-RH antagonists of formula (IIb), one to 16 times per day (in the case of pulsatile administration).

55 Oral administration of peptides according to the invention is preferentially effected using gastro-resistant and delayed enteric or colonic release formulations which can be coated pills or tablets containing two or more components, hardened gelatin capsules, special polymeric macro-, micro- or nano-beads containing them, or any device designed to protect them from gastrointestinal degradation and to release them when needed. All other formulations to be taken

orally such as solutions, suspensions, syrups, gels and the like, or lingual, sublingual or chewable formulations are suited provided that the dosage is increased.

Overall, effective oral treatment may be achieved with any of the above formulations with unit doses of peptides of formula (I) ranging from 1 mg to 1 g per human patient, from one to 16 times per day (in the case of pulsatile administration).

All the above-mentioned oral or parenteral formulations of the peptides according to the invention and their pharmaceutical acceptable salts may contain one or several pharmaceutically appropriate excipients, one or several inhibitors of proteases, and one or several absorption enhancers as needed by the specific route of administration.

Raw powder of pure peptides according to the invention or their pharmaceutically acceptable salts can also be

used, especially in the lyophilized form for fast sublingual application.

The invention will now be described with reference to the following examples, which are not intended to limit the invention in any respect. In these examples, the starting materials used were either commercially available or synthesized, as mentioned below:

- Fmoc-Glu-OH, Fmoc-Tyr(OBut)-OH, Fmoc-Trp-OH and Fmoc-His(Trt) were purchased from Pro peptide (France).
- Fmoc-β-Nal-OH and Fmoc-pClPhe were synthesized as racemates. These amino acids and their corresponding acetyl ethylesters were enzymatically resolved using subtilisin (5) :
- Other Fmoc protected amino-acids were purchased from Bachem (Switzerland), Novabiochem (Switzerland), American Peptide Co (USA) or Neosystem (France).

EXAMPLE 1 : pGlu-His-Trp-Ser-Tyr-Gly-Npg-Arg-Pro-Gly-NH₂

Example 1 was synthesized on a Rink resin using a Fmoc strategy as mentioned above in the genes synthesis of the invention peptides. Cleavage was carried out with TFA in the presence of scavengers.

Purification was carried out using a linear gradient of from 10 to 40 % of eluent B (CH₃CN/0.1 % TFA 60/40 v/v) over 30 min.

68 mg (approximate yield 24 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1195.3
found : 1195.7

net peptide content 73.9% ; purity 97.2% ; retention time 16.4 min.

EXAMPLE 2: pGlu-His-Trp-Ser-Tyr-Gly-Npg-Arg-Pro-NEt

The synthesis was carried out on Boc-Pro-PAM resin. The second amino acid, arginine, was also incorporated via a Boc strategy. The subsequent amino acids were incorporated via a Fmoc strategy. After coupling of the N-terminal amino acid, the peptide was cleaved from the resin and converted into ethylamide by aminolysis using ethylamine (5 ml of ethylamine per gram of peptide resin for 20 hours, -78°C).

After cleavage the protected peptide was extracted with methanol, dried and deprotected with HF as described.

Purification was carried out using a linear gradient of from 10 to 60% of eluent B over 30 min. 15 mg (approximate yield 8%) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1166.3
found : 1166.8

net peptide content 72.7% ; purity 95.0 % ; retention time 15.1 min.

EXAMPLE 3 : pGlu-His-Trp-Ser-Tyr-D-Ala-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for Example 1.

Purification was carried out using a linear gradient of from 10 to 50 % of eluent B over 30 min.

66 mg (approximate yield 27 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1209.4
found : 1209.5.

5 net peptide content 72.6% ; purity 95.2 % ; retention time 14.5 mm.

EXAMPLE 4 : pGlu-His-Trp-Ser-Tyr-D-Ala-Npg-Arg-Pro-NEt

10 Assembling and cleavage of the peptide were carried out as described for Example 2.
Purification was carried out using a linear gradient of from 10 to 60 % of eluent B over 30 min.
8 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

15 expected : 1180.3
found : 1181.0

net peptide content 69.5 % ; purity 96.9 % ; retention time 17.7 min.

20 EXAMPLE 5 : pGlu-His-Trp-Ser-Tyr-D-Leu-Npg-Arg-Pro-Gly-NH₂

Assembling ad cleavage of the peptide were carried out as described for Example 1.
Purification was carried out using a linear gradient of from 15 to 50 % of eluent B over 30 min.
25 123 mg (approximate yield 36%) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

30 expected : 1251.4
found : 1251.9

net peptide content 71.7 % ; purity 95.7 % ; retention time 13.9 min.

EXAMPLE 6 : pGlu-His-Trp-Ser-Tyr-D-Leu-Npg-Arg-Pro-NEt

35 Assembling and cleavage of the peptide were carried out as described for Example 2.
Purification was carried out in two steps, the first one using a linear gradient of from 15 to 50 % of eluent B over 30 min., and the second one using a linear gradient of from 15 to 40 % of eluent B over 30 min.
49 mg (approximate yield 20 %) of purified material were obtained.

40 Mass spectral analysis - ES⁺ mode :

expected : 1222.4
found : 1223.6 (MH⁺)

45 net peptide content 73.6 % ; purity 95.3 % ; retention time 14.6 min.

EXAMPLE 7: pGlu-His-Trp-Ser-Tyr-D-Npg-Npg-Arg-Pro-Gly-NH₂

50 Assembling and cleavage of the peptide were carried out as described for Example 1.
Purification was carried out in two steps, the first one using a linear gradient of from 30 to 60 % of eluent B over 30 min., and the second one using a linear gradient of from 25 to 60 % of eluent B over 30 min.
13 mg (approximate yield 4%) of purified material were obtained.

55 Mass spectral analysis -ES⁺ mode :

expected : 1265.5
found 1266.0

net peptide content 71.1 % ; purity 97.8% ; retention time 15.1 min.

EXAMPLE 8: pGlu-His-Trp-Ser-Tyr-D-Npg-Npg-Arg-Pro-NEt

5 Assembling and cleavage of the peptide were carried out as described for Example 2.
Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.
13 mg (approximate yield 4%) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

10 expected : 1236.4
found : 1237.5 (MH⁺)

net peptide content 68.5 % ; purity 96.2 % ; retention time 13.9 min.

EXAMPLE 9 : pGlu-His-Trp-Ser-Tyr-D-Phe-Npg-Arg-Pro-Gly-NH₂

15 The synthesis was carried out as described for example 1.
Purification was carried out using a linear gradient of from 25 to 80 % of eluent B over 30 min.
20 61 mg (approximate yield 16 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

25 expected : 1285.5
found : 1286.2 (MH⁺)

net peptide content 71.8 % ; purity 96.8 % ; retention time 14.9 min.

EXAMPLE 10 : pGlu-His-Trp-Ser-Tyr-D-Phe-Npg-Arg-Pro-NEt

30 Assembling and cleavage of the peptide were carried out as described for example 2.
Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.
6 mg (approximate yield 4 %) of purified material were obtained.

35 Mass spectral analysis - ES⁺ mode :

expected : 1256.4
found : 1257.4 (MH⁺)

40 net peptide content 63.2 % ; purity 96.9 % ; retention time 13.9 min.

EXAMPLE 11: pGlu-His-Trp-Ser-Tyr-D-Trp-Npg-Arg-Pro-Gly-NH₂

45 Assembling and cleavage of the peptide were carried out as described for example 1.
Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.
22 mg (approximate yield 7 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

50 expected : 1324.5
found : 1325.5 (MH⁺)

net peptide content 71.6% ; purity 97.1 % ; retention time 13.1 min.

EXAMPLE 12: pGlu-His-Trp-Ser-Tyr-D-Trp-Npg-Arg-Pro-NEt

Assembling and cleavage of the peptide were carried out as described for example 2.
Purification was carried out using a linear gradient of from 20 to 80 % of eluent B over 30 min.

10 mg (approximate yields 5 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

5 expected : 1295.4
 found : 1296.3 (MH⁺)

net peptide content 71.3 % ; purity 98.4% ; retention time 13.8 min.

10 EXAMPLE 13: pGlu-His-Trp-Ser-Tyr-D-Nal-Npg-Arg-Pro-Gly-NH₂

Assembling and cleavage of the peptide were carried out as described for example 1.
Purification was carried out using a linear gradient of from 15 to 75 % of eluent B over 30 min.
205 mg (approximate yield 50 %) of purified material were obtained.

15 Mass spectral analysis - ES⁺ mode :

expected : 1335.6
 found : 1336.2 (MH⁺)

20 net peptide content 74.8%; purity 95.6% ; retention time 14.9 min.

EXAMPLE 14: pGlu-His-Trp-Ser-Tyr-D-Nal-Npg-Arg-Pro-NEt

25 Assembling and cleavage were carried out as described for example 2.
Purification was carried out using a linear gradient of from 25 to 50 % of eluent B over 30 min.
82 mg (approximate yield 22 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

30 expected : 1306.5
 found : 1307.2 (MH⁺)

net peptide content 76.0% ; purity 97.4% ; retention time 15.8 min.

35 EXAMPLE 15 : AcD-Nal-D-pClPhe-D-Pal-Ser-NicLys-D-NicLys-Npg-IprLys-Pro-D-Ala-NH₂

The synthesis was carried out on a 4-methylbenzhydrylamine resin.
D-alanine and proline were introduced using a Boc strategy as described above for the general synthesis of the
40 invention peptides. The other amino acids were incorporated via a Fmoc strategy as described above.
The synthesis was started with Boc-D-Ala-OH.
The peptides were deprotected and cleaved from the resin using HF as described above.
Purification was carried out using a linear gradient of from 15 to 70 % of eluent B over 30 min.
49 mg (approximate yield 31 %) of purified material were obtained.

45 Mass spectral analysis - ES⁺ mode :

expected : 1605.3
 found : 1605.5

50 net peptide content 67.6% ; purity 98.3 % ; retention time 15.5 min.

EXAMPLE 16: AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Npg-Arg-Pro-D-Ala-NH₂

55 Assembling and cleavage of the peptide were carried out as described for example 15, arginine being introduced
using a Boc strategy.
Purification was carried out using a linear gradient of from 30 to 60 % of eluent B over 30 min.
16 mg (approximate yield 9 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

expected : 1444.9
found : 1444.6

5 net peptide content 67.1 % ; purity 97.0% ; retention time 16.8 min.

EXAMPLE 17: AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Npg-IprLys-Pro-D-Ala-NH₂

10 Assembling and cleavage of the peptide were carried out as described for Example 15.
Purification was carried out using a linear gradient of from 10 to 60 % of eluent B over 30 min.
55 mg (approximate yield 29 %) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

15 expected value : 1459.9
found : 1459.3

net peptide content 69.8 % ; purity: 96.4% ; retention time 11.2 min.

20 EXAMPLE 18 : AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-HCit-Npg-IprLys-Pro-D-Ala-NH₂

Assembling and cleavage of the peptide were carried out as described for example 15.
Purification was carried out using a linear gradient of from 30 to 50 % of eluent B over 30 min.
25 40 mg (approximate yield 17%) of purified material were obtained.

Mass spectral analysis - ES⁺ mode :

30 expected : 1473.2
found : 1473.2

net peptide content 69.8 % ; purity 95.7 % ; retention time 15.9 min.

EXAMPLE 19: AcD-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-HCit-Npg-Arg-Pro-D-Ala-NH₂

35 Assembling and cleavage of the peptide were carried out described for example 16.
Purification was carried out using a linear gradient of from 30 to 60% of eluent B over 30 min.
55 mg (approximate yield 21 %) of purified material were obtained.

40 Mass spectral analysis - ES⁺ mode :

expected : 1459.1
found : 1459.2

45 net peptide content 68.2% ; purity 96.6% ; retention time 15.7 min.

REFERENCES

- (1) G. BARANY and R.B. MERRIFIELD (1979)
50 The Peptides, , Analysis, Synthesis, Biology, Vol. 2, Chapter 1.
- (2) E. ATHERTON and R.C. SHEPPARD (1989)
Solid phase peptide synthesis, IRL Press, OXFORD
- (3) D. Le NGUEN, A. HEITZ and B. CASTRO (1987)
J. Chem. Soc. Perkin Trans. I, 1915
- (4) E. KAISER, R.L. COLESCOTT, C.D. BOSSINGER and P.I. COOK (1970)
Anal. Biochem., 34, 595
- (5) P.N. RAO, J.E. BURDETT Jr, J.W. CESSAD, C.M. DI NUNNO, D.M. PETERSON and H.K. KIM (1987)
55 Int. J. Pept. Protein Res., 29, 118

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:
(A) NAME: Laboratoire Theramex
(B) STREET: 6, Avenue du Prince Hereditaire Albert
(C) CITY: Monaco
(E) COUNTRY: Monaco
(F) POSTAL CODE (ZIP): 98000
(G) TELEPHONE: 377 92 05 08 08
(H) TELEFAX: 377 92 05 70 00

10 (ii) TITLE OF INVENTION: LH-RH peptide analogues, their uses and pharmaceutical compositions containing them.

15 (iii) NUMBER OF SEQUENCES: 5

20 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

25 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION:/note= "Xaa is pGlu ; D-pGlu ; Sar ; AcSar ; Pro ; AcPro ; ForPro ; OH-Pro ; Ac-OH-Pro ; dehydro-Pro ; Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an optionally acylated aromatic D-amino acid"

35 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2
(D) OTHER INFORMATION:/note= "Xaa is a direct bond : His ; or an aromatic D-amino acid"

40 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 3
(D) OTHER INFORMATION:/note= "Xaa is an aromatic L- or D-amino acid"

45 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4
(D) OTHER INFORMATION:/note= "Xaa is Ala, Ser, D-Ser, MeSer, Ser(OBut), Ser(OBzl) or Thr"

50 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION:/note= "Xaa is an aromatic L-amino acid or a basic L- or D-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:6

(D) OTHER INFORMATION:/note= "Xaa is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBut) ; D-Asp(OBut) ; D-Glu(OBut) ; D-Thr(OBut) ; D-Cys(OBut) ; D-Ser(OR1) where R1 is a sugar moiety ; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C1-C6)alkyl or by a (C2-C7)acylgroup ; an aliphatic D-amino acid with a (C1-C8)alkyl or a (C3-C6)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid"

10 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:7

(D) OTHER INFORMATION:/note= " Xaa may be N-alpha-substituted by a (C1-C4)alkyl group which may be substituted by one or several fluorine atoms"

15 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:8

(D) OTHER INFORMATION:/note= "Xaa is a basic L- or D-amino acid"

20 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:10

(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂ ; or a group -NHR₂ where R₂ is an optionally substituted (C1-C4)alkyl "

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO: 2:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:1

(D) OTHER INFORMATION:/note= "Xaa is pGlu, Sar or AcSar"

40 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:2

(D) OTHER INFORMATION:/note= "Xaa is His"

45 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:3,4,6,7

(D) OTHER INFORMATION:/note= " Xaa may be N-alpha-substituted by a (C1-C4)alkyl group which may be substituted by one or several fluorine atoms"

50 (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:5

(D) OTHER INFORMATION:/note= "Xaa is an aromatic L-amino acid"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION:8
(D) OTHER INFORMATION:/note= "Xaa is a basic L-amino acid"

5 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:10
(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂, azaGlyNH₂ or a group -NHR₂
where R₂ is as defined for SEQ ID NO:1"

10 (xi) SEQUENCE DESCRIPTION: SEQ_ID NO: 2:

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
1 5 10

(2) INFORMATION FOR SEQ_ID NO: 3:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:1,3,4,5,7,8
(D) OTHER INFORMATION:/note= " Xaa may be N-alpha-substituted by a
(C1-C4)alkyl group which may be substituted by one or several fluorine atoms"

25 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:2
(D) OTHER INFORMATION:/note= "Xaa is a direct bond or an aromatic
D-amino acid"

30 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "Xaa is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys
; D-Met; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBut) ; D-Asp(OBut) ; D-Glu(O-But)
; D-Thr(O-But) ; D-Cys(O-But) ; D-Ser(O-R1) where R1 is a sugar moiety ; an
aliphaticD-amino acid with a (C1-C8)alkyl or a (C3-C6)cycloalkyl side chain ; an
aromatic D-aminoacid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ;
D-perhydrodiphenyl-Ala ; or a basicL- or D-amino acid"

35 (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:10
(D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ or D-AlaNH₂"

40 (xi) SEQUENCE DESCRIPTION: SEQ_ID NO: 3:

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa
1 5 10

45 (2) INFORMATION FOR SEQ_ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

50 (iii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-sites
 (B) LOCATION:1
 (D) OTHER INFORMATION:/note= "Xaa is pGlu"

5 (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION: 6
 (D) OTHER INFORMATION:/note= "Xaa is Gly ; an aliphatic D-amino acid with

a (C1-C8)alkyl side chain ; or an aromatic D-amino acid"

10 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION:7
 (D) OTHER INFORMATION:/note= " Xaa may be N-alpha-substituted by a (C1-C4)alkyl group which may be substituted by one or several fluorine atoms"

15 (ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:10
 (D) OTHER INFORMATION:/note= "Xaa is GlyNH₂ or a group -NHC₂H₅"

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Xaa His Trp Ser Tyr Xaa Xaa Arg Pro Xaa
 1 5 10

(2) INFORMATION FOR SEQ ID NO: 5:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION:1
 (D) OTHER INFORMATION:/note= "Xaa is Ac-D-Nal"

35 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION:2
 (D) OTHER INFORMATION:/note= "Xaa is D-pClPhe"

40 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION:3
 (D) OTHER INFORMATION:/note= "Xaa is D-Pal"

45 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION:5,8
 (D) OTHER INFORMATION:/note= "Xaa is as defined for SEQ ID NO:3"

(ix) FEATURE:
 (A) NAME/KEY: Modified-site
 (B) LOCATION:6
 (D) OTHER INFORMATION:/note= "Xaa is Gly or a basic L- or D-amino acid"

50 (ix) FEATURE:
 (A) NAME/KEY: Modified-sites
 (B) LOCATION: 7
 (D) OTHER INFORMATION:/note= " Xaa may be N-alpha-substituted by a

(C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms"

- (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:10
(D) OTHER INFORMATION:/note= "Xaa is D-AlaNH₂"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

10 Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Pro Xaa
1 5 10

15

Claims

- 1 A LLL RU peptide analogue, in which Npa^7 is substituted for Leu^7 ; and its pharmaceutically acceptable salts.

2. A peptide according to claim 1, of the formula (SEQ ID N°: 1):

in which:

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro ; AcPro ; ForPro ; OH-Pro ; Ac-OH-Pro ; dehydro-Pro ; Ac-dehydro-Pro ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated;
 - A2 is a direct bond ; His ; or an aromatic D-amino acid;
 - A3 is an aromatic L- or D-amino acid;
 - A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu¹), Ser(OBzl) or Thr;
 - A5 is an aromatic L-amino acid or a basic L- or D-amino acid;
 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ; D-Ser(OR₁) where R₁ is a sugar moiety; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₆)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;
 - Npg may be N-alpha-substituted by a (C₁-C₄)alkyl group which may be substituted by one or several fluorine atoms;
 - A7 is a basic L- or D-amino acid;
 - Z is GlyNH₂ ; D-AlaNH₂ ; azaGlyNH₂; or a group -NHR₂ where R₂ is a (C₁-C₄)alkyl which may be substituted by one or several fluorine atoms, a (C₃-C₆)cycloalkyl or a heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl; and its pharmaceutically acceptable salts.

- 3 A peptide according to claim 2, of the formula (SEQ ID N° : 2):


15 3. A peptide according to claim 1
A1-A2-A3-A4-A5-A6-Npg-A7-Pro-Z (IIIa)

in which:

- A1 is pGlu, Sar or AcSar;
 - A2 is His;
 - A3 and A4 are as defined for (I) in claim 2;
 - A5 is an aromatic L-amino acid;
 - A6 is Gly ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu¹) ; D-Asp(OBu¹) ; D-Glu(OBu¹) ; D-Thr(OBu¹) ; D-Cys(OBu¹) ; D-Ser(OR₁) where R₁ is a sugar moiety; an aza-amino acid; D-His which may be substituted on the imidazole ring by a (C₁-C₆)alkyl or by a (C₂-C₇)acyl group ; an aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic D-amino acid;
 - Npg is as defined for (I) in claim 2;
 - A7 is a basic L-amino acid;

- Z is GlyNH₂, azaGlyNH₂ or a group -NHR₂ where R₂ is as defined for (I) in claim 2; and its pharmaceutically acceptable salts.


4. A peptide according to claim 2, of the formula (SEQ ID N° : 3):



in which:

- A1 as defined for (I) in claim 2;
- A2 is a direct bond or an aromatic D-amino acid;
- A3, A4 and A5 are as defined for (I) in claim 2;
- A6 is Gly; D-Pro; D-Ser; D-Thr; D-Cys; D-Met; D-Pen; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(O-Bu^t) ; D-Thr(O-Bu^t) ; D-Cys(O-Bu^t) ; D-Ser(O-R₁) where R₁ is a sugar moiety ; a aliphatic D-amino acid with a (C₁-C₈)alkyl or a (C₃-C₆)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;
- Npg and A7 are as defined for (I) in claim 2;
- Z is GlyNH₂ or D-AlaNH₂ ; and its pharmaceutically acceptable salts.

5. A peptide according to claim 3, of the formula (SEQ ID N° : 4):



in which:

- A6 is Gly ; an aliphatic D-amino acid with a (C₁-C₈)alkyl side chain ; or an aromatic D-amino acid;
- Npg is optionally N-alpha-methylated;
- Z is GlyNH₂ or a group -NHC₂H₅ ; and its pharmaceutically acceptable salts.

6. A peptide according to claim 4, of the formula (SEQ ID N° : 5):



in which:

- A5 is as defined for (IIb) in claim 4;
- A6 is Gly or a basic L- or D- amino acid;
- Npg is optionally N-alpha-methylated;
- A7 is as defined for (IIb) in claim 4 ; and its pharmaceutically acceptable salts.

7. A pharmaceutical composition which contains a effective amount of a peptide according to any one of claims 1 to 6, or of a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to claim 7 for oral or parenteral administration.

9. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of infertility, hypogonadic or hypergonadic states, wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.

10. Use of a peptide according to any one of claims 1 to 6 for the preparation of a contraceptive agent, wherein said peptide is used alone or in combination with a sex steroid or a gonadotrophin.

11. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prevention of prostate cancer or benign prostatic hypertrophy, wherein said peptide is used alone or in combination with an androgen action inhibitor, a 5 α -reductase inhibitor or a C₁₇₋₂₀ lyase inhibitor.

12. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prevention of breast cancer, wherein said peptide is used alone or in combination with an antiestrogen, an aromatase inhibitor or a C₁₇₋₂₀ lyase inhibitor.

13. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or pre-

vention of sex hormone-related benign or malignant tumors, wherein said peptide is used alone or in combination with a hormonal or antitumoral agent.

- 5 14. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prevention of sex hormone-independent but LH-RH sensitive benign or malignant tumors, wherein said peptide is used alone or in combination with an antitumoral agent.
- 10 15. Use of a peptide according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prevention of benign or malignant lymphoproliferative disorders, wherein said peptide is used alone or in combination with an immunomodulating agent or an immunosuppressive agent.
- 15 16. Use of a peptide of formula (IIa) or (IIIa) according to claim 3 or 5 for the preparation of a medicament having LH-RH agonist activity.
- 20 17. Use of a peptide of formula (IIb) or (IIIb) according to claim 4 or 6 for the preparation of a medicament having LH-RH antagonist activity.

20

25

30

35

40

45

50

55




FIG. 1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 97 40 1212

DOCUMENTS CONSIDERED TO BE RELEVANT												
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)									
A	<p>CHEMICAL ABSTRACTS, vol. 96, no. 1, 4 January 1982 Columbus, Ohio, US; abstract no. 7042, XP002038873 * abstract * & J.-L. FAUCHERE ET AL.: "Synthesis of gamma-methyl-L-leucine (neopentylglycine) and derivatives suitable for peptide synthesis" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 18, no. 3, COPENHAGEN DK, pages 249-255, ---</p> <p>J. HLAVACEK ET AL.: "Synthesis and biological properties of cholecystokinin heptapeptide analogues containing tert-leucine or neopentylglycine in position 5" COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 56, 1991, PRAGUE CS, pages 2209-2217, XP002038995 ---</p> <p>M.J. KARTEN, J.E. RIVIER: "Gonadotropin-releasing hormone analog design." ENDOCRINE REVIEWS, vol. 7, no. 1, 1986, pages 44-66, XP002038872 * the whole document *</p> <p>-----</p>		C07K7/23									
A			TECHNICAL FIELDS SEARCHED (Int.Cl.6) C07K									
A												
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search THE HAGUE</td> <td>Date of completion of the search 20 October 1997</td> <td>Examiner Cervigni, S</td> </tr> <tr> <td colspan="3"> CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> </tr> <tr> <td colspan="3"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				Place of search THE HAGUE	Date of completion of the search 20 October 1997	Examiner Cervigni, S	CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		
Place of search THE HAGUE	Date of completion of the search 20 October 1997	Examiner Cervigni, S										
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document												
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document												

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

**IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**